NOVNライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (26 7月 2023 @ 05:00):

Stats
本日の出来高	6.93M
平均出来高	1.04M
時価総額	2.64M
EPS	$0 ( 2024-03-28 )
次の収益日	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.112
ATR14	$0.103 (183.93%)

Insider Trading

Date	Person	Action	Amount	type
2023-06-27	Sanders Machelle	Sell	11 553	Common Stock
2023-06-06	John A. Donofrio	Buy	85 000	Restricted Stock Units
2023-06-06	Gay John M.	Buy	200 000	Restricted Stock Units
2023-06-07	Gay John M.	Buy	65 000	Common Stock
2023-06-06	Gay John M.	Buy	65 000	Restricted Stock Units

INSIDER POWER
60.94
Last 97 transactions
Buy: 4 746 863 \| Sell: 340 227

ボリューム相関

長: -0.41 (neutral)

短: -0.55 (weak negative)

Signal:(24.752) Neutral

Novan Inc 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Novan Inc 相関 - 通貨/商品

-0.12
( neutral )

-0.78
( moderate negative )

0.00
( neutral )

-0.40
( neutral )

-0.43
( neutral )

0.08
( neutral )

Novan Inc 財務諸表

Annual	2023
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$0

FY	2023
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$0

FY	2022
収益:	$23.61M
総利益:	$16.23M (68.74 %)
EPS:	$-0.890

FY	2021
収益:	$2.96M
総利益:	$0.00 (0.00 %)
EPS:	$-1.740

Financial Reports:

No articles found.

Novan Inc

Novan, Inc., a pre-commercial nitric oxide-based pharmaceutical company, focuses on dermatology and anti-infective therapies. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company also develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. Novan, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.